Future Outlooks for CAR T in Early R/R Multiple Myeloma

During a live event, Patrick Moore, MD, discussed the KarMMa-3 subgroup analyses and quality of life for patients with relapsed/refractory multiple myeloma.

In this episode of Targeted Talks, Binod Dhakal, MD, MS, discusses the recent FDA approval of ciltacabtagene autoleucel for the treatment of relapsed/refractory multiple myeloma.

Anita D'Souza, MD, discussed the results from the MajesTEC-2 and TRIMM-2 trials in patients with multiple myeloma.

In this episode of Targeted Talks, Ben Derman, MD, dissects the latest advancements in myeloma treatment, focusing on the role of ClonoSeq and minimal residual disease monitoring.

During a live event, John L. Wagner, MD, moderated a discussion on when to refer patients for CAR T-cell therapy and what challenges the referral process poses.

During a Case-Based Roundtable® event, Robert Z. Orlowski, MD, PhD, discussed the case of a patient who had progression of multiple myeloma after quadruplet frontline with transplant.